57062-14-3

Basic information

• Product Name: 2,4-PYRIDINEDICARBONYL DICHLORIDE
• Synonyms: 2,4-PYRIDINEDICARBONYL DICHLORIDE
• CAS NO: 57062-14-3
• Molecular Formula: C₇H₃Cl₂NO₂
• Molecular Weight: 204.012
• Mol File: 57062-14-3.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2,4-PYRIDINEDICARBONYL DICHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-PYRIDINEDICARBONYL DICHLORIDE(57062-14-3)
• EPA Substance Registry System: 2,4-PYRIDINEDICARBONYL DICHLORIDE(57062-14-3)

Safety Data

• Hazardous Substances Data: 57062-14-3(Hazardous Substances Data)

Usage

Physical form

Yellow-brown crystalline powder

Melting point

205-212°C

Uses

Intermediate in the production of pharmaceuticals, dyes, and agricultural chemicals; building block in organic synthesis; preparation of pyridine-based molecules; catalyst in various chemical reactions

Reactivity

Strong and selective towards primary and secondary amino groups

Safety precautions

Can be harmful if ingested, inhaled, or absorbed through the skin. Proper protective equipment and handling procedures should be followed.

Upstream product

• 499-80-9 pyridine-2,4-dicarboxylic acid 

Downstream Products

• 117517-22-3 N,N'-diethyl-2,4-pyridinedicarboxamide 
• 21071-04-5 2,4-Bis(hydroxymethyl)pyridin 
• 501938-32-5 2,4-dibenzoylpyridine 
• 947414-89-3 2,4-bis(1-phenyl-1-pyrrolylmethyl)pyridine 
• 947414-88-2 2,4-bis(phenylhydroxymethyl)pyridine 
• 20857-17-4 2,4-diacetylpyridine 
• 1246534-88-2 C₃₃H₂₅N₅O₄ 
• 1246534-81-5 C₂₃H₂₁N₅O₄ 
• 1246534-80-4 C₂₃H₂₁N₅O₆ 
• 1246534-87-1 C₂₅H₂₅N₅O₆ 
• 1246534-84-8 C₂₃H₂₁N₅O₆ 
• 1246534-79-1 C₂₁H₁₇N₅O₄ 
• 1246534-83-7 C₂₁H₁₅Cl₂N₅O₄ 
• 1246534-82-6 C₂₃H₂₁N₅O₄ 

Relevant articles and documents

Discovery of novel dehydroabietic acid derivatives as DNA/BSA binding and anticancer agents

To explore the biological properties of rosin derivatives, two dehydroabietic acid derivatives N-(5-dehydroabietyl-1,3,4-thiadiazole)-yl-pyridine-2-carboxamide (DTPC) and di-N-(5-dehydroabietyl-1,3,4-thiadiazole)-yl-pyridine-2,6-carboxamide (DDTPC) with 1,3,4-thiadiazole, pyridine and amide moieties were designed and synthesized according to superposition principle of activity group. They interact with calf thymus DNA (CT DNA) via intercalation based on the results of circular dichroism (CD) and fluorescence spectroscopy, DNA denaturation and viscosity studies. Fluorescence and CD spectral experiments indicate that they might be transported and stored by protein like bovine serum albumin (BSA). MTT assay was further carried out to examine their cytotoxicity, they both showed selective cytotoxicity and DTPC exhibited better cytotoxicity. The antiproliferative effect of DTPC toward A431 cell line was stronger than that of clinically used cisplatin and oxaliplatin. In addition, the cytotoxicity of DTPC and DDTPC was closely related with their DNA binding ability.

Synthesis and Biological Evaluation of Oral Prodrugs Based on the Structure of Gemcitabine

A series of oral prodrugs based on the structure of gemcitabine (2′,2′-difluorodeoxycytidine) were synthesised by introducing an amide group at the N4-position of the cytidine ring. A total of 16 compounds were obtained, and their chemical and biological characteristics were evaluated. The half-maximal inhibitory concentrations (IC50s) for most of these compounds were higher than that of gemcitabine in vitro. Compounds 5d and 5m, the representative compounds, were examined in terms of their physiological stabilities and pharmacokinetics. Compound 5d showed good stability in PBS and simulated intestinal fluid, and an analysis of its pharmacokinetics in mice suggested that the introduction of an amide group to gemcitabine could greatly improve its bioavailability. Further evaluation of compound 5din vivo showed that this compound possesses higher activity than gemcitabine against the growth of HepG2 human hepatocellular carcinoma cells and HCT-116 colon adenocarcinoma cells with less toxicity to animals. These results suggest that compound 5d could be further developed as a potential oral anticancer agent for clinical applications in which gemcitabine is currently used. A series of oral prodrugs based on the structure of gemcitabine were synthesized. Physiological and metabolic stabilities, pharmacokinetics and antitumor activities were evaluated for representative compounds.

Aromatic and nonaromatic pyriporphyrins

Pyriporphyrins with three different orientations for the pyridine moiety have been prepared using a '3 + 1' strategy. The nonaromatic pyriporphyrins are stable so long as phenyl substituents are present at the meso-positions adjacent to the pyridine ring. An aromatic dihydropyriporphyrin with an external CO 2Ph protective group has also been prepared from 2,4- pyridinedicarbaldehyde.